Clinical Research Directory
Browse clinical research sites, groups, and studies.
The Efficacy of Long-Chain Fatty Acids, Eicosapentaenoic Acid (EPA) and Specialized Pro-Resolving Mediators (SPMs), in Treating Long COVID Neuropsychiatric Symptoms
Sponsor: National Science and Technology Council, Taiwan
Summary
Researchers conducted a 12-week, double-blind, randomized, placebo-controlled trial to assess the effectiveness of EPA or SPM treatments versus a placebo in managing Long COVID symptoms in adult patients. Researchers planned to enroll 240 eligible participants from various general and psychiatric hospitals in Taiwan. The focus was on evaluating the therapeutic impact and potential side effects of administering 3 g/day of EPA or 1.67 mg/day of SPMs on symptoms of depression in these patients. This consolidated approach aims to provide comprehensive insights into the efficacy of EPA and SPM treatments in Long COVID cases, addressing crucial mental health aspects.
Official title: Eicosapentaenoic Acid and Specialized Pro-Resolving Mediator for Depressive Symptoms in Long COVID: A Randomized Controlled Trial
Key Details
Gender
All
Age Range
20 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
54
Start Date
2024-06-01
Completion Date
2026-06-01
Last Updated
2026-07-21
Healthy Volunteers
No
Interventions
Eicosapentaenoic acid (omega-3 fatty acid)
A total daily dose of 3 g, administered as six capsules
Specialized Pro-Resolving Lipid Mediator
A total daily dose of 1.67 g, administered as six capsules
Placebo
Six capsules containing soybean oil daily
Locations (1)
Mind-Body Interface Research Center (MBI Lab & Care)
Taichung, Taichung, Taiwan